Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Kelbæk, Henning ; Yeh, Robert W ; Engstrøm, Thomas ; Neumann, Franz-Josef ; Serruys, Patrick W ; Windecker, Stephan ; Belardi, Jorge ; Qiao, Shubin ; Xu, Bo ; Liu, Minglei ; Silber, Sigmund. / Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions. In: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2021 ; Vol. 16, No. 16. pp. 1326-1332.

Bibtex

@article{cc26cff5c4e64ad7bc07dccf33ef6b06,
title = "Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions",
abstract = "AIMS: Reports of long-term outcomes of patients treated with drug-eluting stents in total coronary occlusions are limited. We analyzed clinical outcomes of patients treated with the zotarolimus-eluting Resolute stent (R-ZES) implanted in total coronary versus non-occluded lesions.METHODS AND RESULTS: Patients treated with R-ZES and included in 4 trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided in 3 groups: patients with chronic total occlusions (CTO), patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5-years were analyzed. Of 5,487 patients treated with R-ZES in these trials, 8.0% had CTO's, 8.5% rec-TO's and 83.5% non-TO's. Patients had a mean age of 62.8 years, approximately 25% were female and 30% diabetics. TLF was similar in the 3 groups at 5 years (TLF was 13.2%, 12.5% and 13.3% in the CTO, rec-TO and non-TO groups, respectively, p=0.96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively, p=0.11).CONCLUSIONS: In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.",
keywords = "Cardiovascular Agents, China/epidemiology, Coronary Artery Disease, Coronary Occlusion/surgery, Drug-Eluting Stents, Female, Humans, Male, Middle Aged, Myocardial Infarction, Percutaneous Coronary Intervention/adverse effects, Prosthesis Design, Sirolimus/analogs & derivatives, Time Factors, Treatment Outcome, Drug-eluting stent, Stable angina, Chronic coronary total occlusion, ACS/NSTE-ACS",
author = "Henning Kelb{\ae}k and Yeh, {Robert W} and Thomas Engstr{\o}m and Franz-Josef Neumann and Serruys, {Patrick W} and Stephan Windecker and Jorge Belardi and Shubin Qiao and Bo Xu and Minglei Liu and Sigmund Silber",
year = "2021",
month = mar,
day = "19",
doi = "10.4244/EIJ-D-19-00866",
language = "English",
volume = "16",
pages = "1326--1332",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "Europa Edition",
number = "16",

}

RIS

TY - JOUR

T1 - Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions

AU - Kelbæk, Henning

AU - Yeh, Robert W

AU - Engstrøm, Thomas

AU - Neumann, Franz-Josef

AU - Serruys, Patrick W

AU - Windecker, Stephan

AU - Belardi, Jorge

AU - Qiao, Shubin

AU - Xu, Bo

AU - Liu, Minglei

AU - Silber, Sigmund

PY - 2021/3/19

Y1 - 2021/3/19

N2 - AIMS: Reports of long-term outcomes of patients treated with drug-eluting stents in total coronary occlusions are limited. We analyzed clinical outcomes of patients treated with the zotarolimus-eluting Resolute stent (R-ZES) implanted in total coronary versus non-occluded lesions.METHODS AND RESULTS: Patients treated with R-ZES and included in 4 trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided in 3 groups: patients with chronic total occlusions (CTO), patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5-years were analyzed. Of 5,487 patients treated with R-ZES in these trials, 8.0% had CTO's, 8.5% rec-TO's and 83.5% non-TO's. Patients had a mean age of 62.8 years, approximately 25% were female and 30% diabetics. TLF was similar in the 3 groups at 5 years (TLF was 13.2%, 12.5% and 13.3% in the CTO, rec-TO and non-TO groups, respectively, p=0.96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively, p=0.11).CONCLUSIONS: In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.

AB - AIMS: Reports of long-term outcomes of patients treated with drug-eluting stents in total coronary occlusions are limited. We analyzed clinical outcomes of patients treated with the zotarolimus-eluting Resolute stent (R-ZES) implanted in total coronary versus non-occluded lesions.METHODS AND RESULTS: Patients treated with R-ZES and included in 4 trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided in 3 groups: patients with chronic total occlusions (CTO), patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5-years were analyzed. Of 5,487 patients treated with R-ZES in these trials, 8.0% had CTO's, 8.5% rec-TO's and 83.5% non-TO's. Patients had a mean age of 62.8 years, approximately 25% were female and 30% diabetics. TLF was similar in the 3 groups at 5 years (TLF was 13.2%, 12.5% and 13.3% in the CTO, rec-TO and non-TO groups, respectively, p=0.96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively, p=0.11).CONCLUSIONS: In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.

KW - Cardiovascular Agents

KW - China/epidemiology

KW - Coronary Artery Disease

KW - Coronary Occlusion/surgery

KW - Drug-Eluting Stents

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Percutaneous Coronary Intervention/adverse effects

KW - Prosthesis Design

KW - Sirolimus/analogs & derivatives

KW - Time Factors

KW - Treatment Outcome

KW - Drug-eluting stent

KW - Stable angina

KW - Chronic coronary total occlusion

KW - ACS/NSTE-ACS

UR - http://www.scopus.com/inward/record.url?scp=85103473324&partnerID=8YFLogxK

U2 - 10.4244/EIJ-D-19-00866

DO - 10.4244/EIJ-D-19-00866

M3 - Journal article

C2 - 31746760

VL - 16

SP - 1326

EP - 1332

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 16

ER -

ID: 59126040